In summary, plasma GFAP, being strictly associated with amyloid co-pathology in ALS, could serve as a biomarker of cognitive impairment in ALS and aid in identifying patients with cognitive features atypical for ALS-FTD dementia. The gene discussed is GFAP; the disease is amyotrophic lateral sclerosis.